It looks like the Libigel extension study is complete clinicaltrials.gov/ct2/show/NCT01235754?term=biosante&rank=1 Extension study In addition to today's media release on the stock for debt swap This transaction will extend BioSante's cash runway and is important as we continue to analyze the best path forward for LibiGelĀ®, I believe they wanted money to further explore the subset data analysis, as the Nutsyprofessor expected.